Previous close | 64.89 |
Open | 64.89 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's range | 64.40 - 65.57 |
52-week range | 44.03 - 79.88 |
Volume | |
Avg. volume | 162,537 |
Market cap | 1.669B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.32 |
Earnings date | 07 Aug 2023 - 11 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 104.33 |
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 33.33% and 1.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, May 08, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023.
Establishment Labs Holdings Inc.'s ( NASDAQ:ESTA ) price-to-sales (or "P/S") ratio of 10.7x might make it look like a...
Surgalign (SRGA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, April 27, 2023--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the "Company"), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the closing of its previously announced public offering of 1,265,000 common shares at $71.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 165,000 additional common shares. The gross proceeds to the
NEW YORK, April 26, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2023 after the market closes on Monday, May 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.
NEW YORK, April 25, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the "Company"), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the pricing of its public offering of 1,100,000 common shares at a price of $71.50 per share. The gross proceeds to Establishment Labs, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be appr
NEW YORK, April 24, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the "Company"), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has commenced a public offering of its common shares, to be sold by the Company in a registered public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common shares to be sold i
NEW YORK, April 24, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the "Company"), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the first quarter of 2023.
NEW YORK, April 20, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today noted the presentation of a study update on the Motiva US IDE Study. The update included three-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also a Principal Investigator in the Study, presented
Key Insights Institutions' substantial holdings in Establishment Labs Holdings implies that they have significant...
NEW YORK, April 10, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced the launch of Mia Femtech™ ("Mia®") in Japan, marking the beginning of a new era in breast aesthetics.
Establishment Labs Holdings Inc. (ESTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NEW YORK, April 03, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2023, which is being held April 19-23 in Miami, Florida.
NEW YORK, March 29, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has surpassed three million Motiva® devices in market.
Block shares are making headlines for all the wrong reasons today, with short-seller Hindenburg Research raising red flags surrounding the company. Whose side are you on?
NEW YORK, March 23, 2023--Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into agreements with four partners in Europe and a second partner chain in Japan for Mia Femtech™ ("Mia®").
Establishment Labs Holdings ( NASDAQ:ESTA ) Full Year 2022 Results Key Financial Results Revenue: US$161.7m (up 28...
NEW YORK, February 28, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 9:50 am Eastern Time.
NEW YORK, February 27, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States. The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 202
The average of price targets set by Wall Street analysts indicates a potential upside of 43% in Establishment Labs Holdings Inc. (ESTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
SANTA BARBARA, Calif., February 13, 2023--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2022, after the market closes on Monday, February 27, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results.
The mean of analysts' price targets for Establishment Labs Holdings Inc. (ESTA) points to a 42.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.